Prakt. lékáren. 2013; 9(3): 131-134

Cannabis or THC, CBD, CB1, CB2 etc.

Jaroslav Peč
Centrum regionu Haná pro biotechnologický a zemědělský výzkum, Oddělení genetických zdrojů zelenin,

Presented short review introduces basic information concerning phytocannabinoids and their relation to the human endocannabinoid

system. Attention is focused on Sativex®, as the only one medicinal preparation containing cannabinoids registered in the Czech

Republic. Based on Sativex® are listed perspectives of medicinal cannabis. Indications, adverse effects, contraindications and possible

drug interactions are listed.

Keywords: tetrahydrocannabinol, cannabidiol, cannabinoid receptor, Sativex, synergism

Published: July 15, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Peč J. Cannabis or THC, CBD, CB1, CB2 etc. Praktické lékárenství. 2013;9(3):131-134.
Download citation

References

  1. Flores-Sanchez IJ, Verpoorte R. Secondary metabolism in Cannabis. Phytochemistry reviews. 2008; 7: 615-639. Go to original source...
  2. http://www.lf.upol.cz/menu/o-fakulte/historie-a-soucasnost/(4. 1. 2013).
  3. Hanuš L. Pharmacological and therapeutic secrets of plant and brain (endo) cannabinoids. Medicinal research reviews. 2009; 29(2): 213-271. Go to original source... Go to PubMed...
  4. Mechoulam R, Hanuš L. A historical overview of chemical research on cannabinoids. Chemistry and physics of lipids. 2000; 108(1-2): 1-13. Go to original source... Go to PubMed...
  5. http://www.sukl.cz/modules/medication/search.php; Souhrn údajů o přípravku Sativex(R), datum revize textu 7. 9. 2012 (4. 1. 2013).
  6. http://www.gwpharm.com/Sativex.aspx (4. 1. 2013).
  7. http://www.cannabisbureau.nl/en/MedicinalCannabis/;Information for health care professionals, verze 11. 12. 2008 (4. 1. 2013).
  8. http://medicalmarijuana.ca (4. 1. 2013).
  9. http://www.hc-sc.gc.ca/dhp-mps/marihuana/med/infoprof-eng.php; Health Canada - Information for health care professionals, verze 9/2010 (4. 1. 2013).
  10. http://www.lecebnekonopi.cz/catalogue/detail/3/54/Lecebne-konopi-zkusenost-z-Izraele (4. 1. 2013).
  11. Klumpers LE, Beumer TL, van Hasselt JGC, et al. Novel ?(9) -tetrahydrocannabinol formulation Namisol(R) has beneficial pharmacokinetics and promising pharmacodynamic effects. British journal of clinical pharmacology 2011; 74(1): 42-53. Go to original source... Go to PubMed...
  12. Pertwee RG. Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. Philosophical transactions of the Royal Society B. 2012; 367(1607): 3353-3363. Go to original source... Go to PubMed...
  13. Baker D, Pryce G, Jackson SJ, Bolton C, Giovannoni G. The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis. Multiple sclerosis and related disorders. 2012;1(2): 64-75. Go to original source... Go to PubMed...
  14. Battista N, Di Tommaso M, Bari M, Maccarrone M. The endocannabinoid system: an overview. Frontiers in behavioral neuroscience. 2012; 6: 1-7. Go to original source... Go to PubMed...
  15. Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimar?es FS. Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philosophical transactions of the Royal Society B. 2012; 367(1607): 3364-3378. Go to original source... Go to PubMed...
  16. Wagner H. Synergy research: approaching a new generation of phytopharmaceuticals. Fitoterapia. 2011; 82(1): 34-37. Go to original source... Go to PubMed...
  17. Karschner EL, Darwin WD, Goodwin RS, Wright S, Huestis MA. Plasma cannabinoid pharmacokinetics following controlled oral delta 9-tetrahydrocannabinol and oromucosal cannabis extract administration. Clinical chemistry. 2011; 57(1): 66-75. Go to original source... Go to PubMed...
  18. Huestis MA. Human Cannabinoid Pharmacokinetics. Chemistry & biodiversity 2007; 4: 1770-1804. Go to original source... Go to PubMed...
  19. http://www.marinol.com;Prescribinginformation (4. 1. 2013).




Pharmacy for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.